St. Petersburg Times
Special report
Video report
  • For their own good
    Fifty years ago, they were screwed-up kids sent to the Florida School for Boys to be straightened out. But now they are screwed-up men, scarred by the whippings they endured. Read the story and see a video and portrait gallery.
  • More video reports
Multimedia report
Print Email this storyEmail story Comment Email editor
Fill out this form to email this article to a friend
Your name Your email
Friend's name Friend's email
Your message

Health and medicine

Stomach, kidney cancer drug okayed

Associated Press
Published January 27, 2006

WASHINGTON - A new drug that combats both a rare stomach cancer and advanced kidney cancer won speedy federal approval Thursday.

Sunitinib, to be marketed by Pfizer Inc. as Sutent, is the first cancer drug to simultaneously win Food and Drug Administration approval for two conditions.

Sutent works by depriving tumor cells of the blood and nutrients needed to grow.

The once-a-day capsule is meant to treat both gastrointestinal stromal tumors and advanced kidney cancer. Pfizer is studying the drug for use in treating other cancers, including breast and lung cancer.

The approval comes a month after the FDA gave approval to sorafenib tosylate, or Nexavar, the first new drug for kidney cancer patients in a decade.

[Last modified January 27, 2006, 01:22:12]

Share your thoughts on this story

[an error occurred while processing this directive]
Subscribe to the Times
Click here for daily delivery
of the St. Petersburg Times.

Email Newsletters